Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Adicet Bio, Inc (ACET)  
$2.19 0.01 (0.45%) as of 4:30 Tue 4/16


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 42,850,000
Market Cap: 93.84(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.11 - $7.13
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 19.7
Insider 6 Months    : 19.7
Insider 3/6 Months : 39.6
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Adicet Bio is a biopharmaceutical company discovering and developing allogeneic gamma delta T cell therapies for cancer. Co.'s product candidate, ADI-001, an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptors (CAR) targeting CD20, is in Phase 1 study for the treatment of Non-Hodgkin's Lymphoma. Co.'s pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15, for the treatment of solid tumors. In addition, Co. is engaged in preclinical stage activities directed to expansion of its pipeline of product candidates for both hematological malignancies and solid tumors.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 6,250,000 6,250,000 8,016,000 8,016,000
Total Buy Value $15,000,000 $15,000,000 $18,684,650 $18,684,650
Total People Bought 2 2 5 5
Total Buy Transactions 2 2 7 7
Total Shares Sold 0 0 11,000 232,611
Total Sell Value $0 $0 $15,291 $3,870,940
Total People Sold 0 0 1 3
Total Sell Transactions 0 0 2 19
End Date 2024-01-18 2023-10-17 2023-04-18 2022-04-18

   
Records found: 165
  Page 1 of 7  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Orbimed Israel Biofund Gp Limited Partnership   –       •       •   2024-01-25 4 B $2.40 $7,500,000 I/I 3,125,000 1,255,985 0.01 -11%     
   Gordon Carl L   –       •       •   2024-01-25 4 B $2.40 $7,500,000 I/I 3,125,000 1,255,985 0.01 -11%     
   Galimi Francesco SVP & Chief Medical Officer   •       –      –    2024-01-24 4 A $0.00 $0 D/D 26,300 101,801     -
   Galimi Francesco SVP & Chief Medical Officer   •       –      –    2024-01-24 4 D $2.40 $11,897 D/D (4,957) 75,501     -
   Harvey Brian Nicholas Chief Financial Officer   •       –      –    2024-01-24 4 A $0.00 $0 D/D 26,300 99,800     -
   Harvey Brian Nicholas Chief Financial Officer   •       –      –    2024-01-24 4 D $2.40 $10,368 D/D (4,320) 73,500     -
   Aftab Blake Chief Scientific Officer   •       –      –    2024-01-24 4 A $0.00 $0 D/D 19,700 62,511     -
   Aftab Blake Chief Scientific Officer   •       –      –    2024-01-24 4 D $2.40 $8,556 D/D (3,565) 42,811     -
   Healey Don Chief Technology Officer   •       –      –    2024-01-24 4 A $0.00 $0 D/D 19,700 72,329     -
   Healey Don Chief Technology Officer   •       –      –    2024-01-24 4 D $2.40 $11,688 D/D (4,870) 52,629     -
   Schor Chen President & CEO   •       •      –    2024-01-24 4 A $0.00 $0 D/D 70,300 208,771     -
   Schor Chen President & CEO   •       •      –    2024-01-24 4 D $2.40 $36,696 D/D (15,290) 138,471     -
   Aftab Blake Chief Scientific Officer   •       –      –    2023-10-12 4 D $1.35 $10,710 D/D (7,933) 46,376     -
   Galimi Francesco SVP & Chief Medical Officer   •       –      –    2023-10-02 4 D $1.37 $11,087 D/D (8,093) 80,458     -
   Harvey Brian Nicholas Chief Financial Officer   •       –      –    2023-10-02 4 D $1.37 $9,722 D/D (7,096) 77,820     -
   Healey Don Chief Technology Officer   •       –      –    2023-10-02 4 D $1.37 $12,425 D/D (9,069) 57,499     -
   Schor Chen President & CEO   •       •      –    2023-10-02 4 D $1.37 $31,795 D/D (23,208) 153,761     -
   Schor Chen President & CEO   •       •      –    2023-10-02 4 B $1.33 $7,340 I/I 5,500 43,469 2.58 150%     
   Schor Chen President & CEO   •       •      –    2023-09-29 4 S $1.36 $7,481 D/D (5,500) 176,969 -147%     
   Schor Chen President & CEO   •       •      –    2023-09-28 4 B $1.42 $7,810 D/D 5,500 182,469 2.81 126%     
   Schor Chen President & CEO   •       •      –    2023-09-28 4 S $1.42 $7,810 I/I (5,500) 37,969 -126%     
   Dubin Steve Director   –       •      –    2023-06-30 4 B $2.40 $12,000 D/D 5,000 10,900 2.39 -46%     
   Gordon Carl L Director   –       •       •   2023-06-27 4 B $2.09 $1,828,750 I/I 875,000 748,054 2.25 -31%     
   Chimovits Erez Director   –       •       •   2023-06-27 4 B $2.09 $1,828,750 I/I 875,000 748,054 2.25 -31%     
   Kauffman Michael Director   –       •      –    2023-06-01 4 A $0.00 $0 D/D 5,900 5,900     -
  165 Records found
  1  2  3  4  5  6  7   
  Page 1 of 7
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us